Skip to main content

Navigation group

Type at least 3 characters
810 articles

Articles

Original Research

Published on 18 Aug 2022

Study protocol for a prospective, open-label, single-arm, phase II study on the combination of tislelizumab, nab-paclitaxel, gemcitabine, and concurrent radiotherapy as the induction therapy for patients with locally advanced and borderline resectable pancreatic cancer

in Gastrointestinal Cancers: Hepato Pancreatic Biliary Cancers

  • Changchang Lu
  • Yahui Zhu
  • Weiwei Kong
  • Ju Yang
  • Linxi Zhu
  • Lei Wang
  • Min Tang
  • Jun Chen
  • Qi Li
  • Jian He
Study protocol for a prospective, open-label, single-arm, phase II study on the combination of tislelizumab, nab-paclitaxel, gemcitabine, and concurrent radiotherapy as the induction therapy for patients with locally advanced and borderline resectable pancreatic cancer
Frontiers in Oncology
doi 10.3389/fonc.2022.879661
  • 3,723 views
  • 2 citations